KEY POINTS
- This retrospective single-center study from The Fourth Hospital of Hebei Medical University, China, evaluated 203 patients with initially positive internal mammary nodes (IMNs) who received neoadjuvant systemic therapy, surgery, and comprehensive adjuvant radiotherapy between 2013 and 2022. IMN involvement was pathologically confirmed in 135 patients (66.5%) and diagnosed by imaging in 68 (33.5%). Following neoadjuvant treatment, 114 patients (56.2%) achieved a clinical complete response in the IMNs. Median follow-up was 73 months.
- Patients were categorized by cumulative IMN radiation dose, calculated as EQD2 using α/β = 4 Gy. The lower-dose group received ≤60 Gy EQD2 (n=83), while the higher-dose group received >60 Gy EQD2 (n=120). Elective regional irradiation generally delivered 45–50.4 Gy in 25–28 fractions, with an optional IMN boost of a median 10 Gy (range 4–16 Gy). Boost selection was individualized according to residual nodal disease, pathological risk factors, and clinical considerations.
- Higher IMN dose was not associated with improved survival after adjustment using stabilized inverse probability treatment weighting. Five-year locoregional recurrence-free survival was 80.8% with ≤60 Gy versus 79.5% with >60 Gy (p=0.346). Five-year recurrence-free survival was 75.8% versus 74.4% (p=0.291), and overall survival was 85.9% versus 80.8% (p=0.149), respectively. These differences were not statistically significant, but the observational design does not establish dose equivalence.
- Three factors independently predicted poorer recurrence-free survival. Multivariable Cox analysis identified cT3–4 disease (HR 2.07, 95% CI 1.13–3.79; p=0.019), Ki-67 >20% (HR 3.41, 95% CI 1.71–6.78; p<0.001), and lymph node ratio >20% (HR 2.08, 95% CI 1.00–4.29; p=0.049) as adverse prognostic factors. No variable remained independently associated with overall survival in the multivariable analysis.
- Post-neoadjuvant IMN response identified substantial prognostic heterogeneity. Among patients with residual radiologically abnormal IMNs, those achieving ≤30% reduction in nodal diameter had markedly poorer five-year outcomes than those achieving >30% reduction: locoregional recurrence-free survival 49.2% versus 91.1%, recurrence-free survival 50.5% versus 87.8%, and overall survival 60.9% versus 94.7% (all p<0.001). However, within the poor-response subgroup, higher IMN dose did not produce a statistically significant survival advantage. In patients with IMN clinical complete response but residual axillary disease, higher dose was associated with inferior recurrence-free survival (63.7% versus 83.7%; p=0.026), an exploratory finding potentially affected by treatment-selection bias.
- Distant metastasis was the dominant failure pattern, while isolated IMN recurrence was rare. Among the 203 patients, 42 (20.7%) developed distant metastases and 16 (7.9%) experienced locoregional recurrence. Only two patients (1.0%) developed IMN recurrence, one in each dose group, and both recurrences occurred within the radiation field. No isolated IMN failure was observed. These findings suggest that systemic disease progression represented a greater challenge than recurrence within the irradiated IMN region.
- Higher IMN dose increased acute skin toxicity without a demonstrated survival benefit. Grade ≥2 acute dermatitis occurred in 37.5% with >60 Gy versus 12.0% with ≤60 Gy (p<0.001), an absolute difference of 25.5 percentage points. Across the full cohort, grade 3 dermatitis occurred in 3.4%, leukopenia in 3.4%, and neutropenia in 2.0%, with no grade 4 toxicities reported. Late cardiovascular events occurred in 5.4% overall, without a statistically significant difference between dose groups. However, the study's retrospective toxicity assessment and nonrandom dose selection limit causal interpretation.
CLINICAL TAKEAWAY
Escalating internal mammary nodal irradiation above 60 Gy EQD2 was not associated with improved five-year disease control or survival in this retrospective post-neoadjuvant breast cancer cohort, while moderate dermatitis was more frequent. The results question routine boost escalation in all initially IMN-positive patients but do not establish the safety of de-escalation, particularly when substantial residual nodal disease persists. Prospective risk-adapted studies are required before changing IMN boost indications or prescriptions.